|
Desoxycorticosterone Pivalate
drug data and news
Desoxycorticosterone Pivalate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Desoxycorticosterone Pivalate
|
| Brand Names/Synonyms |
BRN 3174879; Cortexone M; DOCP; DTMA; Deoxycorticosterone Pivalate; Deoxycorticosterone Trimethylacetate; Deoxycortolone Pivalate; Deoxycortone Pivalate; Deoxycortone Trimethylacetate; Desoxycorticosterone Pivalate; Desoxycorticosterone Trimethylacetate; Desoxycortone Pivalate; NSC 95278; Neodin-Depositum; Percorten; Percorten M; Percorten Pivalate |
| Indication |
For treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Used to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium. |
| Mechanism Of Action |
Desoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration. |
Desoxycorticosterone Pivalate News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
CREAM; SUSPENSION; IMPLANTATION; PELLET |
| Drug_Category |
Diuretics; Anti-Addison Agents; ATC:H02A |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement. |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
[2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl]2,2-dimethylpropanoate |
| Chemical Formula |
C26H38O4 |
| Molecular Weight |
414.578 g/mol |
| Smiles String |
CC12CCC3C(C1CCC2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CCC34C |
| Melting Point |
Not Available |
| Water Solubility |
Insoluble |
| State |
Solid |
| LogP/Hphobicity |
5.544 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
90% |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00709 |
| CAS Registry Number |
808-48-0 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
SID:156479 |
| PharmGKB ID |
PA449245 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2139227
|
|
|
